header image

Page 45«..1020..44454647..5060..»

Archive for Pet Stem Cell Therapy

Sick of sourdough bread yet? 5 sourdough dishes beyond the basic loaf: empanadas, waffles, popovers, crepes and crackers – San Antonio Express-News

At the onset of the COVID-19 outbreak, the coronavirus wasnt the only bug America became obsessed with. Practically overnight, seemingly every American now flush with time and boredom started to bake sourdough bread.

Flour and yeast disappeared from grocery store shelves. Boundless boules and batards both popular sourdough loaf shapes spread faster than any virus on countless social media threads. Home baked bread was back, and in a big way.

But like any new lifestyle we love to crow about on social media a new fitness routine, the Whole30 challenge, selling essential oils beginners enthusiasm sometimes outstripped the reality of the commitment that keeping sourdough starter alive demands. Many ghosted on their bready crush, seeking fulfillment elsewhere. But for a lucky masochistic few, a lifelong passion ignited.

I killed my starter twice. It really was like feeding a pet, said Katie Kinder DeBauche, the vice president of development at the Witte Museum. She was working from home and had played with sourdough a few times before.

She named her starter Dolores after the Westworld character Dolores Abernathy, whos known for regenerating multiple times after death. Kinder DeBauche, made sure to keep a portion of Dolores as a backup in the fridge just in case. Id forget about her on the counter. Shes been reincarnated twice.

On ExpressNews.com: Sourdough is back, connecting new generations of bakers with starters decades old

San Antonio chef Dave Terrazas found himself laid off from his job with Mercy Chefs and getting familiar with yeast, flour and water at the onset of the coronavirus outbreak as well. From March into the early summer, Terrazas could be found in his kitchen stirring, kneading and baking up loaves of sourdough bread. Hed had an on-again-off-again relationship with sourdough before the pandemic.

But his efforts went onto a back burner once the heat cranked up. His starter, which never received a name, has passed on to the great, bubbly beyond.

Once the garden season went into full swing around May, that was just so time consuming, Terrazas said. He helped plant about a half-dozen gardens for himself and fellow culinary professionals. The camaraderie and fun of building gardens kind of took over.

For both, the sourdough adventure led to learning a lot about bread and what else sourdough starter can become.

The sourdough starter feeding process involves generating a considerable quantity of what bakers often call discard, or a portion of starter thats no longer needed after a fresh feeding. That discard is loaded with a wide range of flavorful and aromatic bacteria and yeast. Many bakers throw it out, but that discard can be used to make countless other things.

Kinder DeBauche said she hated that waste, so she looked for recipes that went beyond the basic loaf.

On ExpressNews.com: No-knead bread still the king of viral recipes

The best and worst thing that happened to me during the quarantine is sourdough waffles. Its not so much the waffle thats bad for you, but what you put on them, she said with a laugh.

Terrazas also found the sourdough discard to be the biggest revelation of his quarantine baking efforts.

Waste not, want not, Terrazas said. It would be a shame wasting a cup or 2 every day. It has all those flavors in it. That flavorful waste product became waffles, empanadas, pasta and more in his kitchen.

Pasta, Terrazas said, was particularly interesting. Typically, pasta doesnt contain any yeast or other leavening agents. The starter, he said, gave his noodles a bounce similar to traditional ramen noodles, which are cooked in water containing one of several kinds of alkaline salt to achieve their unique texture.

On ExpressNews.com: 4 oven-free icebox pies: Margarita, chocolate, lemon and dulce de leche

Playing with sourdough gave both Terrazas and Kinder DeBauche other creative and professional outlets, as well.

For Kinder DeBauche, baking became a way to connect with her family. Her great grandparents were immigrant bakers from Poland who settled in New Jersey. Shes documented the process of teaching herself to bake on her blog at katiesmidnightbaker.com. Shes also turned her baking exploits into a side hustle selling batches of Parker House rolls made from her familys secret recipe.

Terrazas saw sourdough as a perfect educational vehicle. In the coming weeks he plans to launch an online program called Foodie Classroom. The website, foodieclassroom.com, will go live in coming weeks.

Foodie Classroom will take the state standards for all the STEM classes and use food as a contextual element. Algebra can be used to upscale a recipe. Geometry can be used to calculate the area of a pizza. Terrazas explained. Ill be filming videos in farms, gardens, parks and kitchens around the city.

And sourdough will play a roll in that education.

Part of the reason for the whole sourdough thing was Foodie Classroom, he said. Ninth grade biology is all about the life cycle of cells.

If, like Terrazas and Kinder DeBauche, you want options for what to do with the starter discard, were providing you with some sourdough recipes that go beyond the basic loaf.

Recipe: Sourdough Waffles

Recipe: Sourdough Empanadas

Recipe: Sourdough Popovers

Recipe: Sourdough Crepes

Recipe: Sourdough Crackers

Recipe: Sourdough Starter

Paul Stephen is a food and drink reporter and restaurant critic in the San Antonio and Bexar County area. To read more from Paul, become a subscriber. pstephen@express-news.net | Twitter: @pjbites | Instagram: @pjstephen

Continued here:
Sick of sourdough bread yet? 5 sourdough dishes beyond the basic loaf: empanadas, waffles, popovers, crepes and crackers - San Antonio Express-News

Biotechnology Could Change the Cattle Industry. Will it Succeed? – Undark Magazine

When Ralph Fisher, a Texas cattle rancher, set eyes on one of the worlds first cloned calves in August 1999, he didnt care what the scientists said: He knew it was his old Brahman bull, Chance, born again. About a year earlier, veterinarians at Texas A&M extracted DNA from one of Chances moles and used the sample to create a genetic double. Chance didnt live to meet his second self, but when the calf was born, Fisher christened him Second Chance, convinced he was the same animal.

Scientists cautioned Fisher that clones are more like twins than carbon copies: The two may act or even look different from one another. But as far as Fisher was concerned, Second Chance was Chance. Not only did they look identical from a certain distance, they behaved the same way as well. They ate with the same odd mannerisms; laid in the same spot in the yard. But in 2003, Second Chance attacked Fisher and tried to gore him with his horns. About 18 months later, the bull tossed Fisher into the air like an inconvenience and rammed him into the fence. Despite 80 stitches and a torn scrotum, Fisher resisted the idea that Second Chance was unlike his tame namesake, telling the radio program This American Life that I forgive him, you know?

In the two decades since Second Chance marked a genetic engineering milestone, cattle have secured a place on the front lines of biotechnology research. Today, scientists around the world are using cutting-edge technologies, from subcutaneous biosensors to specialized food supplements, in an effort to improve safety and efficiency within the $385 billion global cattle meat industry. Beyond boosting profits, their efforts are driven by an imminent climate crisis, in which cattle play a significant role, and growing concern for livestock welfare among consumers.

Gene editing stands out as the most revolutionary of these technologies. Although gene-edited cattle have yet to be granted approval for human consumption, researchers say tools like Crispr-Cas9 could let them improve on conventional breeding practices and create cows that are healthier, meatier, and less detrimental to the environment. Cows are also being given genes from the human immune system to create antibodies in the fight against Covid-19. (The genes of non-bovine livestock such as pigs and goats, meanwhile, have been hacked to grow transplantable human organs and produce cancer drugs in their milk.)

But some experts worry biotech cattle may never make it out of the barn. For one thing, theres the optics issue: Gene editing tends to grab headlines for its role in controversial research and biotech blunders. Crispr-Cas9 is often celebrated for its potential to alter the blueprint of life, but that enormous promise can become a liability in the hands of rogue and unscrupulous researchers, tempting regulatory agencies to toughen restrictions on the technologys use. And its unclear how eager the public will be to buy beef from gene-edited animals. So the question isnt just if the technology will work in developing supercharged cattle, but whether consumers and regulators will support it.

Cattle are catalysts for climate change. Livestock account for an estimated 14.5 percent of greenhouse gas emissions from human activities, of which cattle are responsible for about two thirds, according to the United Nations Food and Agriculture Organization (FAO). One simple way to address the issue is to eat less meat. But meat consumption is expected to increase along with global population and average income. A 2012 report by the FAO projected that meat production will increase by 76 percent by 2050, as beef consumption increases by 1.2 percent annually. And the United States is projected to set a record for beef production in 2021, according to the Department of Agriculture.

For Alison Van Eenennaam, an animal geneticist at the University of California, Davis, part of the answer is creating more efficient cattle that rely on fewer resources. According to Van Eenennaam, the number of dairy cows in the United States decreased from around 25 million in the 1940s to around 9 million in 2007, while milk production has increased by nearly 60 percent. Van Eenennaam credits this boost in productivity to conventional selective breeding.

You dont need to be a rocket scientist or even a mathematician to figure out that the environmental footprint or the greenhouse gases associated with a glass of milk today is about one-third of that associated with a glass of milk in the 1940s, she says. Anything you can do to accelerate the rate of conventional breeding is going to reduce the environmental footprint of a glass of milk or a pound of meat.

Modern gene-editing tools may fuel that acceleration. By making precise cuts to DNA, geneticists insert or remove naturally occurring genes associated with specific traits. Some experts insist that gene editing has the potential to spark a new food revolution.

The question isnt just if the technology will work in developing supercharged cattle, but whether consumers and regulators will support it.

Jon Oatley, a reproductive biologist at Washington State University, wants to use Crispr-Cas9 to fine tune the genetic code of rugged, disease-resistant, and heat-tolerant bulls that have been bred to thrive on the open range. By disabling a gene called NANOS2, he says he aims to eliminate the capacity for a bull to make his own sperm, turning the recipient into a surrogate for sperm-producing stem cells from more productive prized stock. These surrogate sires, equipped with sperm from prize bulls, would then be released into range herds that are often genetically isolated and difficult to access, and the premium genes would then be transmitted to their offspring.

Furthermore, surrogate sires would enable ranchers to introduce desired traits without having to wrangle their herd into one place for artificial insemination, says Oatley. He envisions the gene-edited bulls serving herds in tropical regions like Brazil, the worlds largest beef exporter and home to around 200 million of the approximately 1.5 billion head of cattle on Earth.

Brazils herds are dominated by Nelore, a hardy breed that lacks the carcass and meat quality of breeds like Angus but can withstand high heat and humidity. Put an Angus bull on a tropical pasture and hes probably going to last maybe a month before he succumbs to the environment, says Oatley, while a Nelore bull carrying Angus sperm would have no problem with the climate.

The goal, according to Oatley, is to introduce genes from beefier bulls into these less efficient herds, increasing their productivity and decreasing their overall impact on the environment. We have shrinking resources, he says, and need new, innovative strategies for making those limited resources last.

Oatley has demonstrated his technique in mice but faces challenges with livestock. For starters, disabling NANOS2 does not definitively prevent the surrogate bull from producing some of its own sperm. And while Oatley has shown he can transplant sperm-producing cells into surrogate livestock, researchers have not yet published evidence showing that the surrogates produce enough quality sperm to support natural fertilization. How many cells will you need to make this bull actually fertile? asks Ina Dobrinski, a reproductive biologist at the University of Calgary who helped pioneer germ cell transplantation in large animals.

But Oatleys greatest challenge may be one shared with others in the bioengineered cattle industry: overcoming regulatory restrictions and societal suspicion. Surrogate sires would be classified as gene-edited animals by the Food and Drug Administration, meaning theyd face a rigorous approval process before their offspring could be sold for human consumption. But Oatley maintains that if his method is successful, the sperm itself would not be gene-edited, nor would the resulting offspring. The only gene-edited specimens would be the surrogate sires, which act like vessels in which the elite sperm travel.

Even so, says Dobrinski, Thats a very detailed difference and Im not sure how that will work with regulatory and consumer acceptance.

In fact, American attitudes towards gene editing have been generally positive when the modification is in the interest of animal welfare. Many dairy farmers prefer hornless cows horns can inflict damage when wielded by 1,500-pound animals so they often burn them off in a painful process using corrosive chemicals and scalding irons. In a study published last year in the journal PLOS One, researchers found that most Americans are willing to consume food products from cows genetically modified to be hornless.

Still, experts say several high-profile gene-editing failures in livestock and humans in recent years may lead consumers to consider new biotechnologies to be dangerous and unwieldy.

In 2014, a Minnesota startup called Recombinetics, a company with which Van Eenennaams lab has collaborated, created a pair of cross-bred Holstein bulls using the gene-editing tool TALENs, a precursor to Crispr-Cas9, making cuts to the bovine DNA and altering the genes to prevent the bulls from growing horns. Holstein cattle, which almost always carry horned genes, are highly productive dairy cows, so using conventional breeding to introduce hornless genes from less productive breeds can compromise the Holsteins productivity. Gene editing offered a chance to introduce only the genes Recombinetics wanted. Their hope was to use this experiment to prove that milk from the bulls female progeny was nutritionally equivalent to milk from non-edited stock. Such results could inform future efforts to make Holsteins hornless but no less productive.

The experiment seemed to work. In 2015, Buri and Spotigy were born. Over the next few years, the breakthrough received widespread media coverage, and when Buris hornless descendant graced the cover of Wired magazine in April 2019, it did so as the ostensible face of the livestock industrys future.

But early last year, a bioinformatician at the FDA ran a test on Buris genome and discovered an unexpected sliver of genetic code that didnt belong. Traces of bacterial DNA called a plasmid, which Recombinetics used to edit the bulls genome, had stayed behind in the editing process, carrying genes linked to antibiotic resistance in bacteria. After the agency published its findings, the media reaction was swift and fierce: FDA finds a surprise in gene-edited cattle: antibiotic-resistant, non-bovine DNA, read one headline. Part cow, part bacterium? read another.

Recombinetics has since insisted that the leftover plasmid DNA was likely harmless and stressed that this sort of genetic slipup is not uncommon.

Is there any risk with the plasmid? I would say theres none, says Tad Sonstegard, president and CEO of Acceligen, a Recombinetics subsidiary. We eat plasmids all the time, and were filled with microorganisms in our body that have plasmids. In hindsight, Sonstegard says his teams only mistake was not properly screening for the plasmid to begin with.

While the presence of antibiotic-resistant plasmid genes in beef probably does not pose a direct threat to consumers, according to Jennifer Kuzma, a professor of science and technology policy and co-director of the Genetic Engineering and Society Center at North Carolina State University, it does raise the possible risk of introducing antibiotic-resistant genes into the microflora of peoples digestive systems. Although unlikely, organisms in the gut could integrate those genes into their own DNA and, as a result, proliferate antibiotic resistance, making it more difficult to fight off bacterial diseases.

The lesson that I think is learned there is that science is never 100 percent certain, and that when youre doing a risk assessment, having some humility in your technology product is important, because you never know what youre going to discover further down the road, she says. In the case of Recombinetics. I dont think there was any ill intent on the part of the researchers, but sometimes being very optimistic about your technology and enthusiastic about it causes you to have blinders on when it comes to risk assessment.

The FDA eventually clarified its results, insisting that the study was meant only to publicize the presence of the plasmid, not to suggest the bacterial DNA was necessarily dangerous. Nonetheless, the damage was done. As a result of the blunder,a plan was quashed forRecombinetics to raise an experimental herd in Brazil.

Sometimes being very optimistic about your technology and enthusiastic about it causes you to have blinders on when it comes to risk assessment.

Backlash to the FDA study exposed a fundamental disagreement between the agency and livestock biotechnologists. Scientists like Van Eenennaam, who in 2017 received a $500,000 grant from the Department of Agriculture to study Buris progeny, disagree with the FDAs strict regulatory approach to gene-edited animals. Typical GMOs are transgenic, meaning they have genes from multiple different species, but modern gene-editing techniques allow scientists to stay roughly within the confines of conventional breeding, adding and removing traits that naturally occur within the species. That said, gene editing is not yet free from errors and sometimes intended changes result in unintended alterations, notes Heather Lombardi, division director of animal bioengineering and cellular therapies at the FDAs Center for Veterinary Medicine. For that reason, the FDA remains cautious.

Theres a lot out there that I think is still unknown in terms of unintended consequences associated with using genome-editing technology, says Lombardi. Were just trying to get an understanding of what the potential impact is, if any, on safety.

Bhanu Telugu, an animal scientist at the University of Maryland and president and chief science officer at the agriculture technology startup RenOVAte Biosciences, worries that biotech companies will migrate their experiments to countries with looser regulatory environments. Perhaps more pressingly, he says strict regulation requiring long and expensive approval processes may incentivize these companies to work only on traits that are most profitable, rather than those that may have the greatest benefit for livestock and society, such as animal well-being and the environment.

What company would be willing to spend $20 million on potentially alleviating heat stress at this point? he asks.

On a windy winter afternoon, Raluca Mateescu leaned against a fence post at the University of Floridas Beef Teaching Unit while a Brahman heifer sniffed inquisitively at the air and reached out its tongue in search of unseen food. Since 2017, Mateescu, an animal geneticist at the university, has been part of a team studying heat and humidity tolerance in breeds like Brahman and Brangus (a mix between Brahman and Angus cattle). Her aim is to identify the genetic markers that contribute to a breeds climate resilience, markers that might lead to more precise breeding and gene-editing practices.

In the South, Mateescu says, heat and humidity are a major problem. That poses a stress to the animals because theyre selected for intense production to produce milk or grow fast and produce a lot of muscle and fat.

Like Nelore cattle in South America, Brahman are well-suited for tropical and subtropical climates, but their high tolerance for heat and humidity comes at the cost of lower meat quality than other breeds. Mateescu and her team have examined skin biopsies and found that relatively large sweat glands allow Brahman to better regulate their internal body temperature. With funding from the USDAs National Institute of Food and Agriculture, the researchers now plan to identify specific genetic markers that correlate with tolerance to tropical conditions.

If were selecting for animals that produce more without having a way to cool off, were going to run into trouble, she says.

A Brahman cow at the University of Floridas Beef Teaching Unit. Visual: Dyllan Furness

There are other avenues in biotechnology beyond gene editing that may help reduce the cattle industrys footprint. Although still early in their development, lab-cultured meats may someday undermine todays beef producers by offering consumers an affordable alternative to the conventionally grown product, without the animal welfare and environmental concerns that arise from eating beef harvested from a carcass.

Other biotech techniques hope to improve the beef industry without displacing it. In Switzerland, scientists at a startup called Mootral are experimenting with a garlic-based food supplement designed to alter the bovine digestive makeup to reduce the amount of methane they emit. Studies have shown the product to reduce methane emissions by about 20 percent in meat cattle, according to The New York Times.

In order to adhere to the Paris climate agreement, Mootrals owner, Thomas Hafner, believes demand will grow as governments require methane reductions from their livestock producers. We are working from the assumption that down the line every cow will be regulated to be on a methane reducer, he told The New York Times.

Meanwhile, a farm science research institute in New Zealand, AgResearch, hopes to target methane production at its source by eliminating methanogens, the microbes thought to be responsible for producing the greenhouse gas in ruminants. The AgResearch team is attempting to develop a vaccine to alter the cattle guts microbial composition, according to the BBC.

Genomic testing may also allow cattle producers to see what genes calves carry before theyre born, according to Mateescu, enabling producers to make smarter breeding decisions and select for the most desirable traits, whether it be heat tolerance, disease resistance, or carcass weight.

Despite all these efforts, questions remain as to whether biotech can ever dramatically reduce the industrys emissions or afford humane treatment to captive animals in resource-intensive operations. To many of the industrys critics, including environmental and animal rights activists, the very nature of the practice of rearing livestock for human consumption erodes the noble goal of sustainable food production. Rather than revamp the industry, these critics suggest alternatives such as meat-free diets to fulfill our need for protein. Indeed, data suggests many young consumers are already incorporating plant-based meats into their meals.

Ultimately, though, climate change may be the most pressing issue facing the cattle industry, according to Telugu of the University of Maryland, which received a grant from the Bill and Melinda Gates Foundation to improve productivity and adaptability in African cattle. We cannot breed our way out of this, he says.

Dyllan Furness is a Florida-based science and technology journalist. His work has appeared in Quartz, OneZero, and PBS, among other outlets.

See the original post:
Biotechnology Could Change the Cattle Industry. Will it Succeed? - Undark Magazine

Veterinary Scholars Symposium Showcases Veterinary Talent And Highlights Need For Continued Innovation In Advancing Animal And Human Health -…

DULUTH, Ga., Aug. 6, 2020 /PRNewswire/ --More than 500 veterinary students from across the U.S., as well as animal health researchers and leaders from three dozen top veterinary schools, convened virtually this week for the Veterinary Summer Scholars Symposium and presentation of the annual Boehringer Ingelheim Research Awards for Graduate Veterinarians and Veterinary Students.

This annual scientific colloquium normally conducted in person -- showcases research by veterinary students completing summer research internships. It provides an opportunity for students in the Boehringer Ingelheim Veterinary Scholars Program to present and discuss research findings. Veterinary Scholars also have the opportunity to network with each other and with mentors from academia, industry and government.

The Boehringer Ingelheim Veterinary Scholars Program was established more than 30 years ago to introduce first- and second-year veterinary medical students to biomedical research. Nearly 4,000 students have received stipends from Boehringer Ingelheim to conduct research since the program started. More information is available at http://veterinaryscholars.boehringer-ingelheim.com/.

At each participating school, Boehringer Ingelheim Veterinary Scholars are assigned a mentor and laboratory. Each scholar conducts a hypothesis-driven research project. The research project is typically conducted over a 10-12 week period during the summer, with students presenting their work at the conclusion. This year, the 35 participating schools quickly deployed alternative plans to comply with COVID-19 safety measures. Some offered lab-based projects to students in a way that provided social distancing and related protections. Others refocused students' research work on projects involving data analysis, which could be conducted offsite.

"We hope that some good can come from the many lessons we have learned during this year's pandemic, such that we can better detect and treat -- or even prevent -- the next pandemic or major threat to human and animal health," said Caroline Belmont, head of U.S. Animal Health Innovation for Boehringer Ingelheim. "Recent events have highlighted how important both innovation and collaboration are in addressing unmet needs in animal and human health. We look forward to the many future contributions today's veterinary students and researchers will make in advancing these efforts."

Students from the more than three dozen veterinary schools participating in the Veterinary Scholars Program are eligible to apply for two annual awards: The Boehringer Ingelheim Veterinary Graduate Award and the Veterinary Research Scholar Award. Winning students receive monetary prizes and a stipend to attend the annual Veterinary Scholars Symposium to accept their awards and present their research.

The 2020 Boehringer Ingelheim Veterinary Graduate Award was presented at the virtual Veterinary Scholars Symposium to Dr. Sara Hamman Osum, a graduate student completing her Ph.D. in the Comparative and Molecular Biosciences Graduate Program at the University of Minnesota's College of Veterinary Medicine.

Dr. Osum's Ph.D. research has focused on developing and characterizing the first porcine model of Neurofibromatosis type 1 (NF1), a devastating neurologic disease for which there is no cure. Before joining the DVM/PhD program at the University of Minnesota, she spent four years as a research associate, studying tolerance and autoimmunity models and fostering her interest in advancing animal welfare through the development of improved animal models for preclinical research. Dr. Osum received her Doctor of Veterinary Medicine from the University of Minnesota in 2016, and her Bachelor of Science in Biology from the University of California in Santa Cruz, Calif., in 2008.

The Boehringer Ingelheim Veterinary Graduate Award promotes research in veterinary biosciences. It recognizes graduate veterinarians who have completed or will soon complete a Ph.D. program or are in their final years of residency training in veterinary pathology, medicine, surgery, radiology/ imaging, or laboratory animal medicine. Recipients receive an honorarium and are invited to present their research at the annual Veterinary Scholars Symposium.

The recipient of the 2020 Boehringer Ingelheim Veterinary Research Scholar Awardis Megan Fahey, a DVM and Ph.D. degree student at Cornell University's College of Veterinary Medicine. Fahey is committed to a career as a veterinary clinician scientist, and her research interests have evolved to focus on zoonotic disease, virology, and immunology. Her work in the Boehringer Ingelheim Veterinary Scholars Program has involved exploration of the use of mesenchymal stem cells to prevent or reduce degeneration in intervertebral disc disease.

Caroline Schlaeppi Fisher, from North Carolina State University's College of Veterinary Medicine, received an honorable mention, 2020Boehringer Ingelheim Veterinary Research Scholar. That distinction recognizes herwork evaluating the effectiveness of reuse and sterilization of certain devices used in veterinary surgery, work intended to help shape evidence-based guidelines for the reuse of these devices.

Boehringer Ingelheim Animal Health The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 10,000 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.

Respect for animals, humans and the environment is at the heart of what we do. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society- threatening diseases.

Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of $4.5 billion (4 billion euros) in 2019 and presence in more than 150 countries.

Boehringer Ingelheim Animal Health has a significant presence in the United States, with more than 3,100 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit http://www.boehringer-ingelheim.us, http://www.facebook.com/BoehringerAHUS or http://www.twitter.com/Boehringer_AH.

Boehringer Ingelheim Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim has been independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

In 2019, Boehringer Ingelheim achieved net sales of $21.3 billion (19 billion euros). Our significant investment of over $3.9 billion (3.5 billion euros) in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

More information about Boehringer Ingelheim can be found at http://www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.

SOURCE Boehringer Ingelheim Animal Health USA Inc.

http://www.boehringer-ingelheim.us

Read more:
Veterinary Scholars Symposium Showcases Veterinary Talent And Highlights Need For Continued Innovation In Advancing Animal And Human Health -...

OpEd: Mayor Needs to Focus on the Real Needs of Our Community says Mike Molina – Maui Time

In a press release dated August 5, 2020, Mayor Victorino responded to the transmission of a proposed resolution I sent to the Governance, Ethics, and Transparency Committee that would seek a settlement to the Hawaii Wildlife Fund, ET AL, v. County of Maui.

The Mayor noted that my actions are highly irresponsible and I am using the Platform to garner votes. I believe the Mayors comments are an over reaction and ill advised. The transmission of the resolution for settlement has no impact on mediation and was not submitted with the intention to interfere with on-going negotiations.

I support continued mediation to resolve this matter once and for all. The proposed resolution for settlement I transmitted will be available to the Council if mediation fails. Its important to recognize that if the past is any indication for how the county fairs in this litigation matter, settlement or negotiations, the county has been on the short end of the stick.

Over the last 8 years, numerous courts have rejected the Countys defense; past settlements have resulted in an additional 5 years of litigation at a cost of over $4 million dollars to county taxpayers in legal fees. Based on past history, Im not holding a lot of faith that mediation will be constructive, however, I am hopeful.

Relative to the Mayors comments that my actions are highly irresponsible and a platform to garner votes, these comments are mean spirited and seek to drive a wedge in collaborative government. Dragging the injection well case over 8 years costing county residents over $4 million dollars is highly irresponsible.

As far as using the platform to garner votes, I am Chair of the Governance, Ethics, and Transparency Committee, it is my job as the Committee Chair, to address settlements and litigation of the County of Maui. Am I using this platform to garner votes, NO, Im using this platform to do my job as assigned to me by the County Council.

My intention in transmitting the proposed resolution for settlement is to provide the Council with an option to end an 8-year nightmare. My focus is to preserve the environment for our future families; reduce impacts to our reef systems, maintain marine life and lessen the dependency on the use of injection wells.

Over the past few months, the county has been hit with a pandemic, the likes of which we have not seen in decades. People are sick, businesses are closing, residents have lost their jobs and people cannot afford to pay rent or mortgages. Our priorities should be to help address these concerns, not spending hundreds of thousands of dollars on attorneys fees.

During these past months, the Mayor has focused his energies on attacking the Council on charter amendments, legislative initiatives and this litigation matter. With all due respect Mr. Mayor, your priorities are wrong. Your focus should be on providing shelter, economic recovery and the health and safety of our community. You are no longer a Councilmember, you are the Mayor, your job is to administer and now is the time to show some leadership.

In May, the Mayor asked for recommendations on how to spend federal assistance for COVID-19. The Council provided excellent recommendations for assistance to our community, however, it took over 3 months for the Mayor to act on the recommendations.

Mr. Mayor, please stop the constant attacking, stop the anger, stop the talk, show some leadership and focus on the real needs of our community.

Mike Molinaholds the County Council seat for the Makawao-Haik-Pia residency area.

comments

Read the original post:
OpEd: Mayor Needs to Focus on the Real Needs of Our Community says Mike Molina - Maui Time

In Depth Analysis and Survey of COVID-19 Pandemic Impact on Global Canine Stem Cell Therapy Coronavirus Impact Editon of Key Players VETSTEM…

Rising number of corona virus cases has impacted numerous lives and led to numerous fatalities, and has affected the overall economic structure globally. The Canine Stem Cell Therapy has analyzed and published the latest report on the global Canine Stem Cell Therapy market. Change in the market has affected the global platform. Along with the Canine Stem Cell Therapy market, numerous other markets are also facing similar situations. This has led to the downfall of numerous businesses, because of the widespread increase of the number of cases across the globe.href=mailto:nicolas.shaw@cognitivemarketresearch.com>nicolas.shaw@cognitivemarketresearch.com or call us on +1-312-376-8303.

Request Free Sample Copy of Canine Stem Cell Therapy Market Research Report@ https://cognitivemarketresearch.com/medical-devicesconsumables/canine-stem-cell-therapy-market-report

The major players in the Canine Stem Cell Therapy market are VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, Stemcellvet . Some of the players have adopted new strategies to sustain their position in the Canine Stem Cell Therapy market. A detailed research study is done on the each of the segments, and is provided in Canine Stem Cell Therapy market report. Based on the performance of the Canine Stem Cell Therapy market in various regions, a detailed study of the Canine Stem Cell Therapy market is also analyzed and covered in the study.

Report Scope:Some of the key types analyzed in this report are as follows: Allogeneic Stem Cells, Autologous Stem cells

Some of the key applications as follow: Veterinary Hospitals, Veterinary Clinics, Veterinary Research Institutes

Following are the major key players: VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, Stemcellvet

An in-depth analysis of the Canine Stem Cell Therapy market is covered and included in the research study. The study covers an updated and a detailed analysis of the Canine Stem Cell Therapy market. It also provides the statistical information of the Canine Stem Cell Therapy market. The study of the report consists of the detailed definition of the market or the overview of the Canine Stem Cell Therapy market. Furthermore, it also provides detailed information for the target audience dealing with or operating in this market is explained in the next section of the report.

Read Detailed Index of full Research Study @: https://cognitivemarketresearch.com/medical-devicesconsumables/canine-stem-cell-therapy-market-report#download_report

The report also provides detailed information on the research methodologies, which are used for the analysis of the Canine Stem Cell Therapy market. The methods are covered in detail in this section of the report. For the analysis of the market, several tools are used for the extraction of the market numbers. Among the several tools, primary and secondary research studies were also incorporated for the research study. These were further analyzed and validated by the market experts, to increase precision and make the data more reliable.

Moreover, the report also highlights and provides a detailed analysis of the drivers, restrains, opportunities, and challenges of the Canine Stem Cell Therapy market. This section of Canine Stem Cell Therapy market also covers the updated information, in accordance with the present situation of the market.

According to the estimation and the analysis of the market, the Canine Stem Cell Therapy market is likely to have some major changes in the estimated forecasts period. Moreover, these changes can be attributed to the changes due to economic and trading conditions across the globe. Moreover, several market players operating in the Canine Stem Cell Therapy market will have to strategically change their business strategies in order to survive in the market.

If Any Inquiry of Canine Stem Cell Therapy Report @: https://cognitivemarketresearch.com/medical-devicesconsumables/canine-stem-cell-therapy-market-report#download_report

Reasons for Buying this Canine Stem Cell Therapy Report1. Canine Stem Cell Therapy market advertise report helps with understanding the Basic product segments alongside likewise their potential future.2. This global Canine Stem Cell Therapy report offers pin-point evaluation for changing competitive dynamics.3. The Canine Stem Cell Therapy market supplies pin point analysis of changing competition dynamics and keeps you in front of competitors4. Original images and illustrated a SWOT evaluation of large segments supplied by the Canine Stem Cell Therapy market.5. This report supplies a forward-looking perspective on different driving factors or controlling Canine Stem Cell Therapy market gain.6. This report assists to make wise business choices using whole insights of the Canine Stem Cell Therapy and also from creating a comprehensive evaluation of market sections.Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

*If you have any special requirements, please let us know and we will offer you the report as you want Click Here>Download Customized Sample Report of Canine Stem Cell Therapy Market Report 2020 (COVID-19 Impact Analysis Updated Edition May 2020)

About Us: Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients. We focus on making sure that based on our reports, our clients are enabled to make most vital business decisions in easiest and yet effective way. Hence, we are committed to delivering them outcomes from market intelligence studies which are based on relevant and fact-based research across the global market.

Contact Us: +1-312-376-8303Email: nicolas.shaw@cognitivemarketresearch.comWeb: https://www.cognitivemarketresearch.com

**********Download the Entire Report*************************************************https://cognitivemarketresearch.com/medical-devicesconsumables/canine-stem-cell-therapy-market-report

Read the original here:
In Depth Analysis and Survey of COVID-19 Pandemic Impact on Global Canine Stem Cell Therapy Coronavirus Impact Editon of Key Players VETSTEM...

Check up: Maybe next week will be better? – Stockhead

Heres our fortnightly wrap of all the news driving ASX health stocks.

Of the ASXs 133-odd small cap health stocks and of those which were trading on Wednesday, 58 were in positive territory over the last fortnight, eight were flat and 67 saw their share prices fall.

No matter which way you cut it, the last fortnight wasnt great for markets. The Small Ords was down almost 1 per cent and the broader market was in a similar state.

Another great rotation, as pundits have taken to calling the big sector sell downs and buy-ins, did not favour health this time with Biotech Dailys Top 40 index falling 2.4 per cent when compared to an ASX200 half percentage point lift in July.

However, fortune favours the bold and investors in Aroa Biosurgery (ASX:ARX) would be pleased with their first fortnight on the market, with the stock up 97 per cent from its IPO on July 24.

Aroa is treading a now familiar path with a wound care product that combines a matrix on which cells can regrow with a treatment for diabetic foot ulcers and venous leg ulcers.

The company is following in the footsteps of Avita (ASX:AVH) and Polynovo (ASX:PNV) which are both successfully treading hospital wards around the world.

Having already put its product through clinical trials and attained US Federal Drug Administration (FDA) approval, it has avoided following the other path trodden by Factor Therapeutics (ASX:FTT), which was trying to cure the same conditions and failed badly.

However Factor is up on the list as well because its board has finally found something to buy: Brain Biosciences, a commercial-stage veterinary medical technology company in the US which is trading as LONGMILE Veterinary PET Imaging.

Chair Dr Cherrell Hirst, who led the long search for the new face of Factor, will retire at the upcoming AGM and be replaced by Dr David Brookes, a rural medicine expert and ASX biotech director.

The deal is still non-binding and subject to due diligence, but this is the first one the Factor board has felt strongly enough about to release publicly.

Its subject to demonstrating to LONGMILE shareholders that Factor has at least $3m in cash when the deal is done and sorting out the board composition, among other things.

Health software company Oneview Healthcare (ASX:ONE) rose after saying installed live devices by the end of June were up 30 per cent on a year ago, and the June quarter saw two customers renew and one extend a contract.

Suda Pharmaceutical (ASX:SUD) finally had its day, after the Therapeutic Goods Administration (TGA) approved several months earlier than unexpected its insomnia mouth spray ZolpiMist.

Suda has been working on ZolpiMist since January 2015 when it licensed zolpidem from Amherst Pharma.

Stem cell play Regeneus (ASX:RGS) has also begun generating some interest among analysts and investors.

It recently updated its negotiating status with Japanese company Kyocera for the osteoarthritis treatment Progenza.

Under the terms of an MOU signed in March, Kyocera has exclusive rights to negotiate a commercial licence for Progenza in Japan. It was supposed to end in July but with talks moving ahead well, they agreed to extend the exclusivity period to the end of August.

And Cogstate (ASX:CGS) moved further ahead with its partnership with Eisai in Japan, which has begun building the brain performance application Easiit, a base element of a digital platform for dementia, that will incorporate Cogstates NouKNOW assessment by the end of September.

Get the latest Stock & Small Caps news and insights direct to your inbox.

It's free. Unsubscribe whenever your want.

You might be interested in

Read more here:
Check up: Maybe next week will be better? - Stockhead

Wound Care Biologics Market By Covid-19 Impact Analysis, Size, Regional Growth, Major Key Players, Technology And Industry Trends Till 2025 – eRealty…

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

To Remain Ahead Of Your Competitors, Request for a FREE Sample Here (with covid 19 Impact Analysis) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&DW

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Make an Enquiry before Buying @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&DW

Based on source, the market is segmented into dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, urine and others. Mesenchymal stem cells are dominating in the market because mesenchymal stem cells (MSCs) are self-renewable, multipotent, easily manageable and customarily stretchy in vitro with exceptional genomic stability. Mesenchymal stem cells have a high capacity for genetic manipulation in vitro and also have good potential to produce. It is widely used in treatment of inflammatory and degenerative disease offspring cells encompassing the transgene after transplantation.

Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules are dominating in the market because bio macromolecules transmit particular biomolecular information and are basically investigated for their delicate properties such as biomarker source and delivery system.

The exosome therapeutic market, by end user, is segmented into hospitals, diagnostic centers and research & academic institutes. Hospitals are dominating in the market because hospitals provide better treatment facilities and skilled staff as well as treatment available at affordable cost in government hospitals.

The major players covered in the report are evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global. Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Read More @ https://www.databridgemarketresearch.com/reports/global-exosome-therapeutic-market?Dw

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email @ [emailprotected]

Visit link:
Wound Care Biologics Market By Covid-19 Impact Analysis, Size, Regional Growth, Major Key Players, Technology And Industry Trends Till 2025 - eRealty...

In the middle of pandemic, this young mom fights second cancer diagnosis – INFORUM

Two years ago, Bustos was happy. She was 20, recently married and had just found out she was pregnant with her first child. Taylor and her husband, Mark, 21, envisioned moving from Duluth to California and raising half a dozen kids. But those plans would have to wait.

Five months into her pregnancy, Bustos felt a lump on her neck. On Oct. 5, 2018, just a month after giving birth to her son, Solomon, she was diagnosed with nodular sclerosis classical Hodgkins lymphoma. Its the most common type of Hodgkins lymphoma, a cancer that affects the bodys immune system.

I was told, This is the good cancer, its curable, Bustos said. She underwent six months of chemotherapy at St. Lukes Radiation Oncology Associates in Duluth and was declared in remission in April 2019. After that, life went pretty much back to normal.

But last November, just before her first follow-up PET CT scan, Bustos prepared for the worst. A few weeks earlier, she had felt the lump in her neck return.

Soon later, she was back at St. Lukes, prepared to receive whatever news may come. Mark tossed a bright pink ball to Solomon to distract the boy and himself from the mounting anxiety as they waited for what felt like an eternity in the small examination room.

The young father was also trying to manage his stress from recently learning he was being laid off from his construction job. The doctor finally stepped in.

Taylor and Mark shared a kiss in their kitchen, taking any quiet moment they can to show their love to one another while raising a one-year-old. Taylor had been diagnosed with Hodgkin's Lymphoma only a month after giving birth to their first son, Solomon. She had just spent the better part of a year battling cancer and was now cancer free. So she was trying to enjoy any sense of normalcy she could. Alex Kormann / Minneapolis Star Tribune/TNS

Im sitting there with a one-year-old and my husband of two years and theyre telling me at 22 years old that I have cancer for the second time, Bustos said.

She had gone into the meeting with the mindset that she would never endure chemotherapy again. It was physically and mentally unlike any other suffering Ive ever gone through in my life and I didnt want to willingly say yes to going back there, Bustos said.

After a week of thinking and praying, Bustos stumbled across a Facebook post from a friend who had recently lost his father in a house fire. His words resonated so deeply with her that she decided she couldnt just lay down and die. This cancer could kill me, but dont I want my sweet son to know I tried? she said.

Once again, she went in for treatments, then slept for three days. The big difference this time was that, to make sure the cancer never came back, she was going to have to follow the doctors next recommendation.

On March 2, the Bustos family picked up and moved 200 miles across the state to Rochester for three months where she would undergo some of the most toxic chemotherapy available at the Mayo Clinic. The mix was so potent that she had to first undergo a stem cell collection; those stem cells would be transplanted afterward to regrow her immune system and other healthy cells decimated by the chemo.

Marks layoff, which at first seemed like a disaster, was now a gift. He could assume a larger role as the family caretaker. Some people might call that luck, but the Bustoss dont believe in luck. For them, it was an act of God.

When it came time to move, Taylors parents, Pam and Jerry, who live across the street from the Bustoses in Duluth, moved with them to help take care of Solomon and Taylor.

It really wasnt a difficult decision, said Jerry, who is a warehouse operator at a Duluth paper supply business.

For me, he said, I would do whatever it takes to get her healthy.

The whole family joined hands and prayed before dinner. God and faith are extremely important to them and has helped Taylor get through this difficult chapter in her life. The COVID-19 pandemic forced church to be held via live stream so Taylor was able to follow along even from 200 miles away. Her faith helped Taylor push through even the darkest moments of treatment. "Knowing I'm in the hands of such a faithful father made it peaceful," she said. Alex Kormann / Minneapolis Star Tribune/TNS

Their family squeezed as much as they could into their two cars, boxes stacked to the roof, rendering the rearview mirror useless. The family settled into a small house only a mile away from the Mayo Clinic.

Just over a week later, COVID-19 hit.

We knew Id have a weakened immune system and wed have to quarantine, Bustos said, but suddenly the whole world had to quarantine, too.

They stayed closely connected with their church through video chat and live streams. In solidarity, her entire family shaved their heads along with Bustos.

A little over a month after moving, Bustos prepared for her most difficult round of chemotherapy. All the effects of normal chemo, including nausea, exhaustion, loss of appetite and body pain would be amplified. And because of the coronavirus, she would be doing it alone. She packed her keyboard piano, a weeks worth of clothes, a few mementos from home and headed to the hospital. She would have to stay in a heavily filtered room by herself for a full week as she underwent treatment.

Masked nurses came and went as Bustos tried to picture what they looked like under all the PPE. Most days, she felt immensely lonely and sad. Originally, she was told shed be able to go home to see her family for one hour per day. The pandemic scrapped those plans. I would cry and nurses couldnt put their hand on my shoulder to tell me, Its OK, because of the coronavirus, Bustos said.

When she was finally able to return to her family a full week later, Bustos was ecstatic. To be able to be hugged was a very welcome relief from despair, she said.

She began to try and process what had happened to her over the last five months. She felt distant from and misunderstood by nearly everyone around her. It can look like its going well from the outside but when you literally want to die, the emotional side of things needs to be handled, she said.

Bustos has since begun therapy and is taking anti-depressants to help manage her mental pain.

As the family moved out of Rochester, the snow was gone. Birds chirped and flowers bloomed; a sign of rebirth and a new beginning.

When they pulled up in front of their apartment in Duluth, chalk drawings graced their sidewalk welcoming them home. Their front door was covered in balloons and a welcome banner was strung across the door frame, all put together by members of Bustoss church youth group.

Bustos collapsed on her old bed. She thought shed feel different in their own apartment, but it oddly felt the same. She had come to realize that home was no longer a physical space. Cancer changed that.

Home for me has become Mark and Solomon, she said, and so whether were in Rochester, Duluth or Timbuktu, Im home when Im with them.

2020 Star Tribune (Minneapolis)

Visit the Star Tribune (Minneapolis) at http://www.startribune.com

Distributed by Tribune Content Agency, LLC.

More here:
In the middle of pandemic, this young mom fights second cancer diagnosis - INFORUM

Antibody testing is increasing, but what do the results mean? – Massive Science

Some 8.7 million years ago, much of what is now Idaho was torched by clouds of hot volcanic ash, destroying all vegetation and animals in sight. The supervolcano, Yellowstone, was erupting. This was Yellowstones largest eruption on record.

Super-eruptions can decimate entire regions, and their cocktail of ash and gases can alter the climate.But, even though they eject huge amounts of material, there are very few documented super-eruptions in the geologic record. So we dont fully understand why they are so big or how often they occur. Now, details of the Yellowstone supervolcanic eruption are documented in a new study published in the journal Geology.

Yellowstones ancient eruptions scattered volcanic debris across the northwestern US. There are so many deposits covering an area tens of thousands of square kilometers that it can be difficult to tell each eruption apart. To get around this, volcanologists collected detailed identifying information, including chemical and chronological data, on each geological deposit.

Volcanic ash from Yellowstone

Wikimedia

When they looked at the data, they found that much of the volcanic debris, which was thought previously to come from repeated smaller eruptions, had the same chemical makeup and age. In fact, these deposits were produced by two previously unrecognized super-eruptions. Both eruptions were searingly hot, and would have baked the landscape in a thick coating of molten volcanic glass. The youngest of the two, known as the Greys Landing super-eruption, is dated to roughly 8.7 million years ago, and, according to the volume of debris released, is 30% larger than all other eruptions recorded from Yellowstone.

Recognition of these events brings Yellowstone's total number of eruptions during the late Miocene to six. That makes for one eruption about every 520,000 years. Since then, however, the pace of eruptions has slowed to once every 1.5 million years.

The evidence seems to suggest that Yellowstone is slowing down. And if this trend continues, the next super-eruption won't happen for another 900,000 years. Predicting eruptions is however a risky business, and the United States Geological Survey still maintain a permanent monitoring network on Yellowstone just in case.

Here is the original post:
Antibody testing is increasing, but what do the results mean? - Massive Science

Stem Cell Therapy for Pets | Windcrest Animal Hospital …

For dogs and cats suffering from osteoarthritis and not getting good results from other treatments, stem cell therapy provides another option. Its a therapy that our veterinarians can also use for treating injuries to the spinal cord, bones, ligaments, and tendons.

Stem cells are a sort of blank slate that can regenerate as any other type of cell. In stem cell therapy, your pets stem cells are taken from their bone marrow, umbilical cord blood, or fat.

Once harvested, the stem cells are then injected into the diseased or injured area. For example, a dog would have stem cells injected in his knee damaged by osteoarthritis. The expectation would be for the cells to move to the damaged tissue, suppressing inflammation, relieving pain, and growing new, healthy tissue.

Currently, we do not offer stem cell services at our Windcrest location. Please visit our nearby Talleyville Veterinary Hospital if you would like to take advantage of stem cell therapy for your pet.

If youd like more information about stem cell therapy as an option for your dog or cat, contact us today to schedule a consultation. Were also available to take care of your pets other needs, including wellness and sick care,

View original post here:
Stem Cell Therapy for Pets | Windcrest Animal Hospital ...

Back to Top